Stocksigma LogoStocksigma Logo

Aarti Drugs FY26 BRSR: PTSCL Unit Closure and Escalated ESG Capex

Aarti Drugs reported FY26 turnover of ₹2,26,038.50 lakhs and net worth of ₹1,40,479.08 lakhs, with exports driving 38% of revenue

Aarti Drugs FY26 BRSR: PTSCL Unit Closure and Escalated ESG Capex

Aarti Drugs Ltd · Others (Uncategorized) · 03 Sept 2026, 3:26 am

Aarti Drugs FY26 BRSR: PTSCL Unit Closure and Escalated ESG Capex Aarti Drugs reported FY26 turnover of ₹2,26,038.50 lakhs and net worth of ₹1,40,479.08 lakhs, with exports driving 38% of revenue. A material regulatory event occurred on 9th Sep'25 when the Maharashtra Pollution Control Board mandated the closure of the chlorosulfonation process at the PTSCL unit following an HCl gas leak, halting production of that specific product. The company increased ESG-focused investments, allocating 15% of total capex and 27% of R&D to environmental improvements. Additionally, 10 of its 12 API manufacturing facilities now operate on Zero Liquid Discharge systems.

Original exchange filing (PDF)

More announcements from Aarti Drugs Ltd

All Aarti Drugs Ltd announcements